TherapeuticsMD Inc (TXMD)

6.16
AMEX : Health Care
Prev Close 6.16
Day Low/High 6.07 / 6.34
52 Wk Low/High 4.39 / 11.26
Avg Volume 3.00M
Exchange AMEX
Shares Outstanding 196.58M
Market Cap 1.21B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's Top Takeaways: TherapeuticsMD, Pioneer Natural Resources

Jim Cramer's Top Takeaways: TherapeuticsMD, Pioneer Natural Resources

With a stock up 400%, what's not to like about Pioneer Natural Resources? Cramer says.

Jim Cramer's 'Mad Money' Recap: The Trump Rally Is Showing Cracks

Jim Cramer's 'Mad Money' Recap: The Trump Rally Is Showing Cracks

Stocks once considered free of risks aren't any longer, Cramer warns.

Positive Clinical Trial Lifts TherapeuticsMD

Stock soars after hours.

Figure 2. Mean Change From Baseline In Weekly Severity Of Moderate To Severe Hot Flashes For Weeks 1 To 12 (Graphic: Business Wire)

Figure 2. Mean Change From Baseline In Weekly Severity Of Moderate To Severe Hot Flashes For Weeks 1 To 12 (Graphic: Business Wire)

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced positive top-line results from its pivotal phase 3 Replenish Trial of TX-001HR, an investigational bio-identical hormone...

Stocks Under $10 Weekly Summary

We booked some profits in Huntington Bancshares and SLM this week and cut our rating on SLM from One to Two.

'Mad Money' Lightning Round: International Paper, Home Depot, Newell Brands

'Mad Money' Lightning Round: International Paper, Home Depot, Newell Brands

Jim Cramer prefers Newell over Berry Plastics and says International Paper is an inexpensive stock with a good yield.

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Cramer wonders if this market has gotten too enthusiastic for the Trump agenda.

TherapeuticsMD's Weakness Is an Opportunity

Our research suggests the risk/reward potential is attractive at current levels.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Charts showing up or down trends in the past week.

Analysts Like 3 Portfolio Names

Builders FirstSource, Huntington Bancshares and TherapeuticsMD all received upbeat outlooks from analysts overnight.

January 2017 Options Now Available For TherapeuticsMD (TXMD)

January 2017 Options Now Available For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD, Inc. saw new options begin trading today, for the January 2017 expiration.

Stocks Under $10 Weekly Summary

We booked some profits in Synovus Financial and used part of the proceeds to buy more Yamana Gold.

Stocks Under $10 Weekly Summary

We sold the rest of our Datalink holdings and will use the proceeds to add a name to our portfolio.

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD To Present At Two Upcoming Investor Conferences

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced that the company will participate in the Stifel 2016 Annual Healthcare Conference on November 15, and the Jefferies 2016 London...

TherapeuticsMD Expands Commercial And Business Development Leadership

TherapeuticsMD Expands Commercial And Business Development Leadership

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced two new strategic hires: Dawn Halkuff as Chief Commercial Officer and Yulii Bogatyrenko as Senior Vice President of Business...

TherapeuticsMD Announces Third Quarter 2016 Financial Results

TherapeuticsMD Announces Third Quarter 2016 Financial Results

TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, today announced its third quarter financial results for the quarter ended September 30, 2016.

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.

June 2017 Options Now Available For TherapeuticsMD (TXMD)

June 2017 Options Now Available For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD, Inc. saw new options begin trading today, for the June 2017 expiration.

TherapeuticsMD To Host Third Quarter Financial Results Conference Call And Webcast On November 3

TherapeuticsMD To Host Third Quarter Financial Results Conference Call And Webcast On November 3

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will host a conference call and live audio webcast to discuss third quarter financial and business results on...

Adding to 2 Positions

We're buying more Builders FirstSource and TherapeuticsMD in a market that is starting the day lower.

Stocks Under $10 Weekly Summary

We used this week's selloff to take positions in a student loan provider and a generic drug maker.

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?

Stocks Under $10 Weekly Summary

September jobs data weighed on indices, while we booked profits in ON Semiconductor and rolled some funds into Yamana Gold.

Stocks Under $10 Weekly Summary

We made several moves in the portfolio during a volatile week, and a slew of economic reports next week could keep the market on edge.

Stocks Under $10 Weekly Summary

U.S. stocks close out week with a modest gain.

TherapeuticsMD Announces Multiple Presentations Related To Yuvvexy™ (TX-004HR) At Two Upcoming Medical Conferences

TherapeuticsMD Announces Multiple Presentations Related To Yuvvexy™ (TX-004HR) At Two Upcoming Medical Conferences

TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced the schedule of nine posters and oral presentations at upcoming medical conferences related to Yuvvexy, the...

Picking Up More TherapeuticsMD

The company is less than 48 hours removed from the latest milestone in its product pipeline, so we'll buy on weakness.

TherapeuticsMD Gains FDA Application Nod

The application is for Yuvvexy, a biosimilar hormone treatment for vulvar and vaginal atrophy.